Avidinorubicin

Avidinorubicin is an antibiotic found in Streptomyces avidinii, exhibiting activity against both Gram-positive and Gram-negative bacteria. Additionally, Avidinorubicin inhibits thrombin (HY-114164) -induced platelet aggregation, with an IC50 of 7.9 μM[1].

Product Specifications

CAS Number

[135447-13-1]

UNSPSC

12352005

Target

Antibiotic; Bacterial

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cardiovascular Disease

Smiles

C[C@@H]1O[C@@H](O[C@@H]2[C@](N)(C[C@H](O[C@H]2C)O[C@@H]3[C@](N)(C[C@H](O[C@H]3C)O[C@@H]4[C@@]5(O[C@H]([C@H]([C@@H]4N(C)C)O)OC6=C7C(C(C(C(O)=C89)=C(C7=O)C(O)=C9C[C@@](O)(C[C@@H]8O[C@H]%10C[C@@H]([C@@H]([C@@H](O%10)C)O)N(C)C)C)=O)=CC=C56)C)C)C)C[C@@H]([C@@H]1OC(CCC(O)=O)=O)OC

Molecular Formula

C60H86N4O22

Molecular Weight

1215.34

References & Citations

[1]Aoki M, et al. Structural studies on avidinorubicin, a novel anthracycline with platelet aggregation inhibitory activity. J Antibiot (Tokyo) . 1991 Jun;44 (6) :635-45.|[2]Yang J, et al. Recent advances in chemical synthesis of amino sugars[J]. Molecules, 2023, 28 (12) : 4724.